Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹24,188 Cr
Revenue (TTM)
₹5,729 Cr
Net Profit (TTM)
₹704 Cr
ROE
9.3 %
ROCE
13.6 %
P/E Ratio
34.3
P/B Ratio
2.7
Industry P/E
80.22
EV/EBITDA
14.5
Div. Yield
1.4 %
Debt to Equity
0
Book Value
₹545.8
EPS
₹42.8
Face value
1
Shares outstanding
164,756,423
CFO
₹4,692.99 Cr
EBITDA
₹8,810.52 Cr
Net Profit
₹6,244.61 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gland Pharma
| -17.4 | 3.0 | 0.7 | -17.2 | -21.1 | -- | -- |
|
BSE Healthcare
| -6.0 | 2.8 | 6.4 | 20.7 | 23.9 | 23.1 | 9.9 |
|
BSE Mid Cap
| -3.0 | 8.5 | 13.3 | 7.4 | 27.3 | 31.4 | 15.6 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Gland Pharma
| -6.7 | 22.1 | -59.2 | 63.1 |
|
BSE Mid Cap
| 25.8 | 45.5 | 1.4 | 39.2 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
1,469.4 | 24,187.9 | 5,729.1 | 704.4 | 15.8 | 8 | 34.3 | 2.7 |
| 15.0 | 21.7 | 79.9 | 2.0 | -- | 5.9 | 10.8 | 0.6 | |
| 139.0 | 50.7 | 52.3 | -0.2 | 4.3 | -0.7 | -- | 1.7 | |
| 70.1 | 35.3 | 99.5 | -4.1 | -2.9 | -7.5 | -- | 0.6 | |
| 401.8 | 2,206.5 | 193.6 | 17.9 | -- | 97 | 89 | 3.0 | |
| 885.6 | 10,619.8 | 6,116.9 | 132.5 | 3.5 | 8.2 | 80.2 | 6.3 | |
| 63.8 | 116.3 | 199.6 | 10.7 | -- | 11.2 | 10.9 | 1.2 | |
| 51.6 | 93.6 | 53.8 | 3.0 | -- | 14.1 | 30.9 | 1.7 | |
| 238.9 | 127.8 | 17.8 | 1.6 | -- | 8.7 | 80.4 | 5.1 | |
| 71.4 | 25.7 | 19.2 | 1.7 | 14.6 | 13.1 | 14.9 | 1.9 |
3 min read•By Udhayaprakash
Gland Pharma IPO: Information Analysis
6 min read•By Danish Khanna
Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products... including synthesis of complex drug molecules, such as LMWH, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro intestinal, gynecological, hormones, neuro/Cns, ophthal/ontological, and other areas, as well as pain and analgesics, respirator, and vitamins, minerals and nutrients; and offers contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. Read more
Incorporated
1978
Chairman
Srinivas Sadu
Managing Director
--
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Gland Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Gland Pharma Ltd stood at ₹ 10,867 Cr as on 31-Dec-24
The share price of Gland Pharma Ltd is ₹1,469.40 (NSE) and ₹1,468.10 (BSE) as of 16-May-2025 15:59 IST. Gland Pharma Ltd has given a return of -21.14% in the last 3 years.
Gland Pharma Ltd has a market capitalisation of ₹ 24,188 Cr as on 16-May-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Gland Pharma Ltd is 2.69 times as on 16-May-2025, a 39% premium to its peers’ median range of 1.93 times.
The P/E ratio of Gland Pharma Ltd is 34.34 times as on 16-May-2025, a 57% discount to its peers’ median range of 80.22 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Gland Pharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Gland Pharma Ltd.
Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products including synthesis of complex drug molecules, such as LMWH, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro intestinal, gynecological, hormones, neuro/Cns, ophthal/ontological, and other areas, as well as pain and analgesics, respirator, and vitamins, minerals and nutrients; and offers contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
The promoter of Gland Pharma Ltd is Fosun Pharma Industrial Pte. Ltd. Fosun Pharma Industrial Pte. Ltd owns 51.83 per cent of the total equity. The chairman of the company is Srinivas Sadu ..
There is no promoter pledging in Gland Pharma Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
10,620
|
|
|
2,206
|
|
|
128
|
|
|
116
|
|
|
94
|
|
|
51
|
|
|
35
|
|
|
26
|
|
|
22
|
| Gland Pharma Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
8.04
|
|
Operating margin(%)
|
15.8
|
|
Net Margin(%)
|
11.86
|
|
Dividend yield(%)
|
1.36
|
Yes, TTM profit after tax of Gland Pharma Ltd was ₹704 Cr.
₹9.10
(
